Latest stories on KYMR
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 | KYMR Stock News
StockTitan50 · neutralgeneral
Guggenheim raises Kymera Therapeutics price target on IRF5 program
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics, Inc. (KYMR) files 8-K
SEC 8-K50 · neutralgeneral
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer | KYMR Stock News
StockTitan56 · neutralproduct/pr
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PR Newswire34 · bearishgeneral
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Yahoo Top48 · neutralgeneral
Kymera's CEO Sold $6 Million in Stock After a 170% Run
The Motley Fool48 · neutralgeneral
Kymera CEO on fast-tracked eczema oral treatment trial
CNBC63 · neutralproduct/pr
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
Seeking Alpha67 · bullishanalyst
Kymera: Building Toward A Defining 2H26 Moment
Seeking Alpha63 · neutralanalyst
Alkami Tech, Diebold Nixdorf See Activist Action
Barron's48 · neutralgeneral
Why Kymera Therapeutics Stock Popped This Week
The Motley Fool67 · bullishproduct/pr
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline
Stocktwits News67 · bullishproduct/pr
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
TipRanks73 · bullishproduct/pr
Kymera Speeds Up KT-621 Development: Phase 2b Atopic Dermatitis Enrollment Finishes Six Months Early, Data Expected by Year-End 2026
MarketChameleon73 · bullishproduct/pr
Kymera climbs after expedited timeline for mid-stage eczema trial
Seeking Alpha73 · bullishproduct/pr
Kymera Completes Enrollment in KT-621 Atopic Dermatitis Trial
TipRanks59 · neutralproduct/pr
Kymera Therapeutics, Inc. (KYMR) files 8-K
SEC 8-K50 · neutralgeneral
Kymera Shareholders Reelect Directors, Affirm Executive Pay, Auditor
TipRanks50 · neutralgeneral
Kymera Therapeutics, Inc. (KYMR) files 8-K
SEC 8-K50 · neutralgeneral
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors | KYMR Stock News
StockTitan50 · neutralgeneral
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Seeking Alpha67 · bullishm&a